Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $126.1 million.

  • Viridian Therapeutics, Inc.\DE's Cash from Investing Activities rose 24890.93% to $126.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.9 million, marking a year-over-year increase of 17123.09%. This contributed to the annual value of -$228.7 million for FY2024, which is 14259.54% down from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Cash from Investing Activities is $126.1 million, which was up 24890.93% from $75.7 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Cash from Investing Activities' 5-year high stood at $126.1 million during Q3 2025, with a 5-year trough of -$180.6 million in Q4 2022.
  • Moreover, its 5-year median value for Cash from Investing Activities was $8.9 million (2022), whereas its average is -$11.1 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Cash from Investing Activities skyrocketed by 1189433.96% in 2021, and later tumbled by 97593.08% in 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Cash from Investing Activities (Quarter) stood at -$80.2 million in 2021, then tumbled by 125.16% to -$180.6 million in 2022, then grew by 6.03% to -$169.7 million in 2023, then skyrocketed by 62.93% to -$62.9 million in 2024, then surged by 300.39% to $126.1 million in 2025.
  • Its last three reported values are $126.1 million in Q3 2025, $75.7 million for Q2 2025, and $100.1 million during Q1 2025.